Nanotechnology Now - Press Release: Drug-device combination opens potential new path to treat stroke:

Home > Press > Drug-device combination opens potential new path to treat stroke:

The novel drug-device combination developed by a team from the Wyss Institute at Harvard University and the New England Center for Stroke Research at University of Massachusetts works quickly to re-vascularize a vessel obstructed by a blood clot. In this schematic, the re-vascularization process is depicted from left to right. The intra-arterial stent is used to open a small channel in the blood clot, restoring enough blood flow to trigger the clot-busting nanotherapeutic which is activated by physical cues of fluid shear force.

Credit: Wyss Institute at Harvard University/New England Center for Stroke Research at the University of Massachusetts

Abstract:
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.

Drug-device combination opens potential new path to treat stroke:

Boston, MA | Posted on October 27th, 2015

In a new study that will appear in the December 2015 issue of Stroke journal, the team co-led by Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., and U. Mass Medical Professor of Radiology Ajay Wakhloo, M.D., Ph.D., FAHA, describe their novel method to quickly dissolve away clots that completely obstruct blood vessels in the brain. Their approach combines an injectable clot-busting nanotherapeutic that targets blockages with an intra-arterial device that restores blood flow to obstructed vessels.

The Wyss Institute nanotherapeutic is composed of an aggregate of biodegradable nanoparticles coated with a clot-busting drug called tissue plasminogen activator (tPA), which mimics the way blood platelets behave inside our own bodies. When blood vessels narrow, the shear force of blood flow increases at that location to produce a physical cue that causes platelets to stick to the vessel wall. Similarly, the nanotherapeutic reacts to fluid shear force, releasing tPA-coated nanoparticles in these narrowed regions where vessels are partially occluded, binding to the blood clot and dissolving it away.

But until now, the mechanically activated nanotherapeutic would not be effective in complete vascular blockages where there is no blood flow, as is the case for most stroke patients. The most effective treatment today for stroke is known as a "stent-retriever thrombectomy" procedure, originally described by Wakhloo and his colleague Matthew Gounis, Ph.D., Associate Professor of Radiology at UMass. The procedure involves placing a small tube through the blockage, passing a closed stent through it, and then opening the stent to physically pull the large blood clot out of the vessel.

"Even with the retriever thrombectomy procedure, not all clots can be removed with a successful outcome," said Gounis. "Clot fragments can be dislodged, which can lead to microclots and tissue damage downstream in the brain circulatory system, and physical dragging of the stent through the vessel can potentially be damaging as well."

Instead, the new advance describes using the stent not to drag out the clot, but to create a narrow channel restoring blood flow through an opening in the center of the vascular blockage. Doing so creates a high level of shear force generated by restored flow, activating the nanotherapeutic to release and target the clot-busting drug along the opened channel in the clot. After the blood clot is fully dissolved, the stent is re-sheathed and harmlessly removed from the vessel. If during the process any clot fragments break off and travel away through the circulatory system, the drug-coated nanoparticles will remain bound to them and continue to dissolve them locally wherever they go.

"What's progressive about this approach is that the temporary opening of a tiny hole in the clot - using a stent device that is already commonly used clinically - results in a local rise in mechanical forces that activate the nanotherapeutic to deploy the clot-busting drug precisely where it can best do its job," said Ingber, who is also the Judah Folkman Professor of Vascular Biology at Boston Children's Hospital and Harvard Medical School and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.

In clinically relevant large animal studies, the team has demonstrated that the drug-device combination works very efficiently, showing that it dissolves clots that fully occlude brain blood vessels that are the same size as they would be in humans.

"This has been a great collaboration between experts in the field of treating stroke and experts in mechanobiology and bioengineering," said co-first author of the study Netanel Korin, Ph.D., former Wyss Technology Development Fellow and current Assistant Professor in Biomedical Engineering at the Technion, Israel, who first described the nanotherapeutic in a 2012 Science publication with Ingber. "We hope that one day it will have a positive impact on patients suffering from a range of medical crises resulting from blood clot occlusions."

####

About Wyss Institute for Biologically Inspired Engineering at Harvard University
The Wyss Institute for Biologically Inspired Engineering at Harvard University uses Nature's design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world. Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing that are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and formation of new startups. The Wyss Institute creates transformative technological breakthroughs by engaging in high risk research, and crosses disciplinary and institutional barriers, working as an alliance that includes Harvard's Schools of Medicine, Engineering, Arts & Sciences and Design, and in partnership with Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Boston Children's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, Charité - Universitätsmedizin Berlin, University of Zurich and Massachusetts Institute of Technology.

About The University of Massachusetts Medical School

The University of Massachusetts Medical School, (www.umassmed.edu) one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $249 million in research funding annually, 80 percent of which comes from federal funding sources. The mission of the Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care.

For more information, please click here

Contacts:
Kat J. McAlpine

617-432-8266

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: